LH (Labcorp Holdings) Short-Term Debt & Capital Lease Obligation : $1,591 Mil (As of Sep. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Labcorp Holdings Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Labcorp Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1,591 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Labcorp Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $6,129 Mil.

Labcorp Holdings Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Labcorp Holdings's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labcorp Holdings Short-Term Debt & Capital Lease Obligation Chart

Labcorp Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

630.10

575.40

199.00

471.10

1,172.00

Labcorp Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															1,159.70	1,172.00	2,219.20	2,208.30	1,590.50

Labcorp Holdings Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Labcorp Holdings Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Labcorp Holdings's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Labcorp Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Labcorp Holdings Inc (NYSE:LH) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

LH:Mexico 0JSY:UK N6B:Germany

Address

358 South Main Street, Burlington, NC, USA, 27215

Website

https://www.labcorp.com

Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Executives

Dwight Gary Gilliland	director	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg	officer: Chief Financial Officer, EVP	P O BOX 1017, CHARLOTTE NC 28201-1017
Amy B. Summy	officer: EVP, Chief Marketing Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Van Der Vaart Sandra D	officer: SVP, Global General Counsel	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Adam H Schechter	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kerrii B Anderson	director	WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Lance Berberian	officer: SVP, Chief Information Officer
Peter J Wilkinson	officer: SVP, Chief Accounting Officer	C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mark S Schroeder	officer: EVP, President-Diagnostics Lab	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman	director	6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber	officer: CEO, Covance Drug Development	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey	officer: EVP, Chief Strategy Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo	officer: EVP, Pres, Central Labs & Intl	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham	officer: EVP, CHRO	C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike	officer: Pres & CEO Clinical Business	C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601